NewCardio (NWCI) Stock Price

NewCardio Price

OTC·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

NewCardio stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of NewCardio over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how NewCardio stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing NewCardio's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

NewCardio Stock Price History
DateNewCardio Price
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
1/29/20260.00 USD
1/28/20260.00 USD
1/27/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/20/20260.00 USD
1/16/20260.00 USD
1/15/20260.00 USD
1/14/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/8/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/30/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/4/20250.00 USD
12/3/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/26/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/18/20250.00 USD
11/17/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/27/20250.00 USD
10/24/20250.00 USD
10/23/20250.00 USD
10/22/20250.00 USD
10/21/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/9/20250.00 USD
10/8/20250.00 USD
10/7/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
10/2/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/29/20250.00 USD
9/26/20250.00 USD
9/25/20250.00 USD
9/24/20250.00 USD
9/23/20250.00 USD
9/22/20250.00 USD
9/19/20250.00 USD
9/18/20250.00 USD
9/17/20250.00 USD
9/16/20250.00 USD
9/15/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/10/20250.00 USD
9/9/20250.00 USD
9/8/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/3/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/27/20250.00 USD
8/26/20250.00 USD
8/25/20250.00 USD
8/22/20250.00 USD
8/21/20250.00 USD
8/20/20250.00 USD
8/19/20250.00 USD
8/18/20250.00 USD
8/15/20250.00 USD
8/14/20250.00 USD
8/13/20250.00 USD
8/12/20250.00 USD
8/11/20250.00 USD
8/8/20250.00 USD
8/7/20250.00 USD
8/6/20250.00 USD
8/5/20250.00 USD
8/4/20250.00 USD
8/1/20250.00 USD
7/31/20250.00 USD
7/30/20250.00 USD
7/29/20250.00 USD
7/28/20250.00 USD
7/25/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

NewCardio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
0.00 USD
-376,000.00 USD
-378,000.00 USD
Jan 1, 2007
0.00 USD
-2.10 M USD
-6.00 M USD
Jan 1, 2008
0.00 USD
-7.83 M USD
-14.94 M USD
Jan 1, 2009
0.00 USD
-10.01 M USD
-10.37 M USD
Jan 1, 2010
257,400.00 USD
-9.46 M USD
-11.50 M USD

NewCardio Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 24, 2026, 8:13 PM
 
EBITM USD
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20062007200820092010
–-2.00-7.00-10.00-9.00
–-6.00-14.00-10.00-11.00
––133.33-28.5710.00
3.9810.9520.9523.7328.64
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales NewCardio generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue NewCardio retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare NewCardio's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares NewCardio has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against NewCardio's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

NewCardio stock margins

The NewCardio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of NewCardio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for NewCardio.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
40.83 %
- %
- %
Jan 1, 2007
40.83 %
- %
- %
Jan 1, 2008
40.83 %
- %
- %
Jan 1, 2009
40.83 %
- %
- %
Jan 1, 2010
40.83 %
-3,674.90 %
-4,466.32 %

NewCardio Stock Revenue, EBIT, Earnings per Share

The NewCardio earnings per share therefore indicates how much revenue NewCardio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
0.00 USD
-0.09 USD
-0.09 USD
Jan 1, 2007
0.00 USD
-0.19 USD
-0.55 USD
Jan 1, 2008
0.00 USD
-0.37 USD
-0.71 USD
Jan 1, 2009
0.00 USD
-0.42 USD
-0.44 USD
Jan 1, 2010
0.01 USD
-0.33 USD
-0.40 USD

NewCardio business model & stock analysis

NewCardio Inc is a leading company in the medical technology industry that specializes in the development and marketing of innovative solutions to improve cardiovascular diagnostics and patient monitoring systems. The company's history began in 2003 when a group of experts and experienced scientists from the medical technology industry decided to develop a new technology together to monitor the electrical activity of the heart. This technology was intended to allow for more accurate diagnosis of cardiovascular diseases and thus provide better treatment options. Over the following years, several patents were filed and the technology was further developed. In 2008, NewCardio Inc was finally founded with the goal of launching the portfolio. NewCardio Inc's business model is based on the development and marketing of CardioBip systems, the company's core technology. The CardioBip system is a non-invasive, wireless, ECG-supported monitoring platform to improve cardiovascular diagnostics. The system is based on the analysis of real-time ECG data transmitted via Bluetooth to a smartphone or other mobile device. The company operates several business areas, including medical technology, clinical trials, and KinetoGen. The medical technology division focuses on the development and marketing of products that improve cardiovascular diagnostics. The CardioBip system is the core product of the medical technology division, but other products such as CardioVolt, CardioCore, and CardioKit are also available. These products offer a variety of features that improve cardiovascular diagnostics and offer numerous applications. The clinical trials division provides support for conducting clinical trials. The company offers digital, wireless ECG monitoring and efficient data analysis to ensure better clinical research. NewCardio's products enable more efficient conduct of clinical trials, saving time and costs. The KinetoGen division is a joint venture with Kineticor, a company that develops technologies for monitoring patients after surgical procedures. The joint venture specializes in the development of products that improve the prognosis and management of postoperative cardiovascular disorders. NewCardio Inc is committed to providing innovative solutions and technologies to improve cardiovascular diagnostics. NewCardio's products are unique in the market as they represent a wireless, non-invasive solution for monitoring cardiovascular diseases. Overall, NewCardio Inc is a unique company whose products and technologies improve cardiovascular diagnostics and optimize patient care. The company is focused on growth and continues to work on developing new innovative solutions to expand its portfolio.

NewCardio SWOT Analysis

Strengths

NewCardio Inc has several strengths that contribute to its success in the market. Firstly, the company offers innovative cardiovascular diagnostic solutions, incorporating state-of-the-art technology and advanced algorithms. By providing accurate and reliable results, NewCardio can fulfill the needs of healthcare professionals and patients alike.

Additionally, NewCardio has a strong team of experienced professionals who possess deep knowledge and expertise in the field of cardiac monitoring. This allows the company to develop cutting-edge products and offer exceptional support to its clients.

Weaknesses

Despite its strengths, NewCardio Inc also faces certain weaknesses that can impact its performance. One significant weakness is the company's limited market presence and brand recognition. This makes it challenging for NewCardio to effectively compete with larger, more established players in the industry.

Additionally, NewCardio's dependence on external suppliers for certain components of its products exposes it to supply chain risks. Any disruptions or delays in the supply chain can adversely affect the company's ability to deliver its solutions in a timely manner, potentially leading to dissatisfied customers.

Opportunities

NewCardio Inc can leverage several opportunities to drive its growth and expand its market share. The increasing prevalence of cardiovascular diseases globally presents a significant opportunity for the company. By offering advanced diagnostic solutions, NewCardio can tap into a growing market and cater to the rising demand for effective cardiac monitoring tools.

Furthermore, the ongoing advancements in technology create opportunities for NewCardio to enhance its existing products or develop new ones. By staying at the forefront of innovation, the company can differentiate itself from competitors and gain a competitive edge in the market.

Threats

NewCardio Inc must be aware of various threats that could impact its business operations. One significant threat is the presence of well-established competitors in the market, who may have greater resources and brand recognition. This puts NewCardio at a disadvantage when it comes to capturing market share and securing partnerships or contracts.

Additionally, regulatory and compliance requirements in the healthcare industry pose threats to NewCardio. Adhering to these regulations can be costly and time-consuming, potentially creating barriers for the company to enter certain markets or expand its product offerings.

NewCardio Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

NewCardio historical P/E ratio, EBIT multiple, and P/S ratio

NewCardio annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

NewCardio shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
3.98 M Stocks
Jan 1, 2007
10.95 M Stocks
Jan 1, 2008
20.95 M Stocks
Jan 1, 2009
23.73 M Stocks
Jan 1, 2010
28.64 M Stocks
Price targets and forecasts for NewCardio are not yet available.

NewCardio Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
11/15/2011-0.08USD130,934.00USD2011 Q3
8/15/2011-0.07USD50,749.00USD2011 Q2
5/12/2011-0.09USD234,464.00USD2011 Q1
3/29/2011-0.03USD225,329.00USD2010 Q4
11/15/2010-0.03USD155,294.00USD2010 Q3

NewCardio Executives and Management Board

VR

Vincent Renz

(54)

President · since 2008

Compensation719,500.00 USD
RB

Mr. Richard Brounstein

(61)

Executive Vice President, Secretary

Compensation204,000.00 USD
JJ

Dr. Jess Jones

(34)

Chief Executive Officer, Director · since 2008

GS

Gregory Sadowski

(39)

Chief Operating Officer

MH

Mr. Michael Hanson

(38)

Independent Director

Frequently asked questions about NewCardio

The business model of NewCardio Inc revolves around providing advanced cardiac monitoring solutions using its innovative technology. By combining signal-processing algorithms with expertise in cardiac electrophysiology, NewCardio offers a unique platform called CardioBip, which enables physicians to accurately evaluate a patient's cardiac health. This non-invasive approach improves the diagnosis and management of cardiovascular diseases, ultimately leading to better patient outcomes. NewCardio's business model focuses on collaborating with healthcare organizations to integrate their technology into existing workflows, enhancing efficiency and accuracy. Through its cutting-edge solutions, NewCardio Inc aims to revolutionize the cardiac monitoring industry and contribute to improved patient care worldwide.

All fundamentals and in-depth analysis of NewCardio

Our stock analysis for NewCardio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NewCardio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

NewCardio Stock
NewCardio Revenue→
NewCardio Stock
NewCardio Net Income→
NewCardio Stock
NewCardio P/E→
NewCardio Stock
NewCardio P/S→
NewCardio Stock
NewCardio EBIT→
NewCardio Stock
NewCardio Dividend→
NewCardio Stock
NewCardio Directors Dealings→
NewCardio Stock
NewCardio Stocks→
NewCardio Stock
NewCardio Market capitalization→
NewCardio Stock
NewCardio Debt→
NewCardio Stock
NewCardio Liabilities→
NewCardio Stock
NewCardio Equity→
NewCardio Stock
NewCardio AAQS→
NewCardio Stock
NewCardio Employees→
NewCardio Stock
NewCardio ROE→
NewCardio Stock
NewCardio ROA→
NewCardio Stock
NewCardio ROCE→
NewCardio Stock
NewCardio News→
NewCardio Stock
NewCardio Analyst Price Targets→

Health Stocks

NewcelXNewbury PharmaceuticalsNewland Pharmaceutical CoNewAmsterdam Pharma CompanyNewron Pharmaceuticals SpANew York Health CareNexalin TechnologyNew Journey Health Technology Group CoNexgelNew Century Healthcare Holding CoNexien BiopharmaNeurotech InternationalAll Stocks A–Z →